Valuation : Insulet Corporation

Market Cap 10.23B 8.8B 8.28B 7.56B 14.15B 966B 14.19B 97.85B 37.97B 495B 38.41B 37.57B 1,596B P/E 2026 *
24x
P/E 2027 * 19.3x
Enterprise Value 10.28B 8.84B 8.32B 7.6B 14.22B 970B 14.26B 98.33B 38.16B 498B 38.59B 37.75B 1,604B EV / Sales 2026 *
3.13x
EV / Sales 2027 * 2.65x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
1 day-2.06%
1 week+1.62%
Current month-0.79%
1 month+10.67%
3 months-3.75%
6 months-38.79%
Current year-48.11%
1 week 142
Extreme 142.005
151.5
1 month 136.46
Extreme 136.46
155.17
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 27/04/2025
Director of Finance/CFO 53 29/09/2025
Compliance Officer 50 30/11/2022
Director TitleAgeSince
Chairman 61 31/12/2018
Director/Board Member 61 26/07/2015
Director/Board Member 59 09/08/2017
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Buy

Chief Executive Officer

1,100 0.0016%
01/08/26 Tax

Head of Human Resources

-244 0.0003%
01/07/26 Free

Director

1,355 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%+1.62%-57.67%-21.12% 10.23B
-0.42%-3.68%-18.51%+7.39% 187B
+1.15%+3.22%+1.37%+17.42% 120B
-1.86%+2.77%+13.15%+91.44% 63.15B
-1.31%-1.09%+17.67%+43.65% 51.75B
-1.54%-2.52%-3.98%-32.30% 50.32B
-2.02%-3.22%+9.18%-12.39% 33.17B
0.00%+3.71% - - 32.1B
-0.81%+0.74%+35.59%-15.78% 23.93B
-1.44%-4.21%-8.07%+11.30% 22.99B
Average -1.03%+0.44%-1.25%+9.96% 59.55B
Weighted average by Cap. -0.58%+0.11%-2.45%+16.23%

Financials

2026 *2027 *
Net sales 3.29B 2.83B 2.66B 2.43B 4.55B 310B 4.56B 31.45B 12.2B 159B 12.35B 12.08B 513B 3.74B 3.22B 3.03B 2.77B 5.18B 354B 5.19B 35.82B 13.9B 181B 14.06B 13.75B 584B
Net income 427M 367M 345M 316M 590M 40.28B 592M 4.08B 1.58B 20.67B 1.6B 1.57B 66.58B 535M 461M 433M 396M 741M 50.54B 743M 5.12B 1.99B 25.93B 2.01B 1.97B 83.54B
Net Debt 49.62M 42.7M 40.17M 36.7M 68.65M 4.69B 68.84M 475M 184M 2.4B 186M 182M 7.74B -322M -277M -261M -238M -446M -30.44B -447M -3.08B -1.2B -15.62B -1.21B -1.18B -50.31B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
04/09/26 US$147.48 -2.06% 1,058,435
03/09/26 US$150.58 +1.65% 1,157,659
02/09/26 US$148.14 -0.16% 1,113,956
01/09/26 US$148.38 -0.19% 1,288,263
31/08/26 US$148.66 +2.43% 6,635,039
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
147.48USD
Average target price
171.91USD
Spread / Average Target
+16.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock